Shares of Vericel Co. (NASDAQ:VCEL) hit a new 52-week high during mid-day trading on Tuesday after HC Wainwright raised their price target on the stock from $26.00 to $44.00. HC Wainwright currently has a buy rating on the stock. Vericel traded as high as $36.80 and last traded at $36.71, with a volume of 8361 shares trading hands. The stock had previously closed at $34.89.
Other equities research analysts have also recently issued reports about the company. Oppenheimer cut Vericel from an “outperform” rating to a “market perform” rating in a research note on Monday. Truist started coverage on Vericel in a research note on Thursday, September 17th. They issued a “buy” rating and a $24.00 price target for the company. ValuEngine cut Vericel from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. Stephens started coverage on Vericel in a research note on Thursday, December 17th. They issued an “overweight” rating and a $31.00 price target for the company. Finally, Zacks Investment Research cut Vericel from a “buy” rating to a “hold” rating in a research note on Saturday, January 9th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $29.75.
In other Vericel news, Director Robert L. Md Zerbe sold 17,500 shares of Vericel stock in a transaction dated Monday, November 23rd. The stock was sold at an average price of $23.55, for a total value of $412,125.00. Following the transaction, the director now owns 34,295 shares in the company, valued at $807,647.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.
The stock has a market cap of $1.68 billion, a P/E ratio of -3,692.00 and a beta of 2.73. The company has a fifty day moving average price of $28.53 and a 200 day moving average price of $20.85.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.11. The company had revenue of $31.02 million for the quarter, compared to the consensus estimate of $30.98 million. During the same quarter last year, the company posted $0.07 EPS. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, analysts predict that Vericel Co. will post -0.12 earnings per share for the current year.
Vericel Company Profile (NASDAQ:VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Read More: Average Daily Trade Volume – ADTV
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.